Outcomes of Percutaneous Coronary Intervention for In-Stent Chronic Total Occlusions: Insights From the PROGRESS-CTO Registry

Evangelia Vemmou; Khaldoon Alaswad; Dimitri Karmpaliotis; Oleg Krestyaninov; Dmitrii Khelimskii; Iosif Xenogiannis; Ilias Nikolakopoulos; Bavana V. Rangan; Emmanouil S. Brilakis

doi:10.1016/j.jcin.2020.05.003

Outcomes of Percutaneous Coronary Intervention for In-Stent Chronic Total Occlusions: Insights From the PROGRESS-CTO Registry

Evangelia Vemmou, Khaldoon Alaswad, Dimitri Karmpaliotis, Oleg Krestyaninov, Dmitrii Khelimskii, Iosif Xenogiannis, Ilias Nikolakopoulos, Bavana V. Rangan, Emmanouil S. Brilakis

Research output: Contribution to journal › Letter › peer-review

6 Scopus citations

Original language	English (US)
Pages (from-to)	1969-1971
Number of pages	3
Journal	JACC: Cardiovascular Interventions
Volume	13
Issue number	16
DOIs	https://doi.org/10.1016/j.jcin.2020.05.003
State	Published - Aug 24 2020

ASJC Scopus subject areas

Cardiology and Cardiovascular Medicine

Access to Document

10.1016/j.jcin.2020.05.003

Cite this

Vemmou, E., Alaswad, K., Karmpaliotis, D., Krestyaninov, O., Khelimskii, D., Xenogiannis, I., Nikolakopoulos, I., Rangan, B. V., & Brilakis, E. S. (2020). Outcomes of Percutaneous Coronary Intervention for In-Stent Chronic Total Occlusions: Insights From the PROGRESS-CTO Registry. JACC: Cardiovascular Interventions, 13(16), 1969-1971. https://doi.org/10.1016/j.jcin.2020.05.003

Vemmou, E, Alaswad, K, Karmpaliotis, D, Krestyaninov, O, Khelimskii, D, Xenogiannis, I, Nikolakopoulos, I, Rangan, BV & Brilakis, ES 2020, 'Outcomes of Percutaneous Coronary Intervention for In-Stent Chronic Total Occlusions: Insights From the PROGRESS-CTO Registry', JACC: Cardiovascular Interventions, vol. 13, no. 16, pp. 1969-1971. https://doi.org/10.1016/j.jcin.2020.05.003

@article{5cd0e0405b77432f9c929dda0b3cd2c1,

title = "Outcomes of Percutaneous Coronary Intervention for In-Stent Chronic Total Occlusions: Insights From the PROGRESS-CTO Registry",

author = "Evangelia Vemmou and Khaldoon Alaswad and Dimitri Karmpaliotis and Oleg Krestyaninov and Dmitrii Khelimskii and Iosif Xenogiannis and Ilias Nikolakopoulos and Rangan, {Bavana V.} and Brilakis, {Emmanouil S.}",

note = "Funding Information: Please note: This work was funded by Abbott Northwestern Hospital Foundation Innovation Grant and a gift from the Joseph F. and Mary M. Fleischhacker Foundation. Study data were collected and managed using Research Electronic Data Capture (REDCap) electronic data capture tools hosted at the Minneapolis Heart Institute Foundation (MHIF), Minneapolis, Minnesota. Dr. Alaswad has received consulting fees from Terumo and Boston Scientific; has been an unpaid consultant for Abbott Laboratories; is a consultant for LivaNova and Teleflex; and is a speaker for Cardiovascular Systems, Inc. Dr. Karmpaliotis has received speaker honoraria from Abbott Vascular, Abiomed, and Boston Scientific; and holds equity in Traverse Vascular, Soundbite, and Saranas. Dr. Rangan has received research funding from the Spectranetics Corporation. Dr. Brilakis has received consulting/speaker honoraria from Abbott Vascular, American Heart Association (associate editor Circulation), Biotronik, Boston Scientific, Cardiovascular Innovations Foundation (board of directors), Cardiovascular Systems, Inc., Elsevier, GE Healthcare, InfraRedx, Medtronic, Siemens, and Teleflex; has received research support from Regeneron and Siemens; and is a shareholder in MHI Ventures. All other authors have reported that they have no relationships relevant to the contents of this paper to disclose. Funding Information: Please note: This work was funded by Abbott Northwestern Hospital Foundation Innovation Grant and a gift from the Joseph F. and Mary M. Fleischhacker Foundation. Study data were collected and managed using Research Electronic Data Capture (REDCap) electronic data capture tools hosted at the Minneapolis Heart Institute Foundation (MHIF), Minneapolis, Minnesota. Dr. Alaswad has received consulting fees from Terumo and Boston Scientific; has been an unpaid consultant for Abbott Laboratories; is a consultant for LivaNova and Teleflex; and is a speaker for Cardiovascular Systems, Inc. Dr. Karmpaliotis has received speaker honoraria from Abbott Vascular, Abiomed, and Boston Scientific; and holds equity in Traverse Vascular, Soundbite, and Saranas. Dr. Rangan has received research funding from the Spectranetics Corporation. Dr. Brilakis has received consulting/speaker honoraria from Abbott Vascular, American Heart Association (associate editor Circulation), Biotronik, Boston Scientific, Cardiovascular Innovations Foundation (board of directors), Cardiovascular Systems, Inc., Elsevier, GE Healthcare, InfraRedx, Medtronic, Siemens, and Teleflex; has received research support from Regeneron and Siemens; and is a shareholder in MHI Ventures. All other authors have reported that they have no relationships relevant to the contents of this paper to disclose.",

year = "2020",

month = aug,

day = "24",

doi = "10.1016/j.jcin.2020.05.003",

language = "English (US)",

volume = "13",

pages = "1969--1971",

journal = "JACC: Cardiovascular Interventions",

issn = "1936-8798",

publisher = "Elsevier Inc.",

number = "16",

}

TY - JOUR

T1 - Outcomes of Percutaneous Coronary Intervention for In-Stent Chronic Total Occlusions

T2 - Insights From the PROGRESS-CTO Registry

AU - Vemmou, Evangelia

AU - Alaswad, Khaldoon

AU - Karmpaliotis, Dimitri

AU - Krestyaninov, Oleg

AU - Khelimskii, Dmitrii

AU - Xenogiannis, Iosif

AU - Nikolakopoulos, Ilias

AU - Rangan, Bavana V.

AU - Brilakis, Emmanouil S.

N1 - Funding Information: Please note: This work was funded by Abbott Northwestern Hospital Foundation Innovation Grant and a gift from the Joseph F. and Mary M. Fleischhacker Foundation. Study data were collected and managed using Research Electronic Data Capture (REDCap) electronic data capture tools hosted at the Minneapolis Heart Institute Foundation (MHIF), Minneapolis, Minnesota. Dr. Alaswad has received consulting fees from Terumo and Boston Scientific; has been an unpaid consultant for Abbott Laboratories; is a consultant for LivaNova and Teleflex; and is a speaker for Cardiovascular Systems, Inc. Dr. Karmpaliotis has received speaker honoraria from Abbott Vascular, Abiomed, and Boston Scientific; and holds equity in Traverse Vascular, Soundbite, and Saranas. Dr. Rangan has received research funding from the Spectranetics Corporation. Dr. Brilakis has received consulting/speaker honoraria from Abbott Vascular, American Heart Association (associate editor Circulation), Biotronik, Boston Scientific, Cardiovascular Innovations Foundation (board of directors), Cardiovascular Systems, Inc., Elsevier, GE Healthcare, InfraRedx, Medtronic, Siemens, and Teleflex; has received research support from Regeneron and Siemens; and is a shareholder in MHI Ventures. All other authors have reported that they have no relationships relevant to the contents of this paper to disclose. Funding Information: Please note: This work was funded by Abbott Northwestern Hospital Foundation Innovation Grant and a gift from the Joseph F. and Mary M. Fleischhacker Foundation. Study data were collected and managed using Research Electronic Data Capture (REDCap) electronic data capture tools hosted at the Minneapolis Heart Institute Foundation (MHIF), Minneapolis, Minnesota. Dr. Alaswad has received consulting fees from Terumo and Boston Scientific; has been an unpaid consultant for Abbott Laboratories; is a consultant for LivaNova and Teleflex; and is a speaker for Cardiovascular Systems, Inc. Dr. Karmpaliotis has received speaker honoraria from Abbott Vascular, Abiomed, and Boston Scientific; and holds equity in Traverse Vascular, Soundbite, and Saranas. Dr. Rangan has received research funding from the Spectranetics Corporation. Dr. Brilakis has received consulting/speaker honoraria from Abbott Vascular, American Heart Association (associate editor Circulation), Biotronik, Boston Scientific, Cardiovascular Innovations Foundation (board of directors), Cardiovascular Systems, Inc., Elsevier, GE Healthcare, InfraRedx, Medtronic, Siemens, and Teleflex; has received research support from Regeneron and Siemens; and is a shareholder in MHI Ventures. All other authors have reported that they have no relationships relevant to the contents of this paper to disclose.

PY - 2020/8/24

Y1 - 2020/8/24

UR - http://www.scopus.com/inward/record.url?scp=85089220514&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85089220514&partnerID=8YFLogxK

U2 - 10.1016/j.jcin.2020.05.003

DO - 10.1016/j.jcin.2020.05.003

M3 - Letter

C2 - 32819493

AN - SCOPUS:85089220514

SN - 1936-8798

VL - 13

SP - 1969

EP - 1971

JO - JACC: Cardiovascular Interventions

JF - JACC: Cardiovascular Interventions

IS - 16

ER -

Outcomes of Percutaneous Coronary Intervention for In-Stent Chronic Total Occlusions: Insights From the PROGRESS-CTO Registry

ASJC Scopus subject areas

Access to Document

Other files and links

Cite this